The impact of genetic risk on the prevalence of advanced fibrosis and cirrhosis in prospectively assessed patients with type 2 diabetes

Documenti analoghi

• A prospective study on the prevalence of at‐risk MASH in patients with type 2 diabetes mellitus in the United States
  di: Nikita Mittal, et al.
  Pubblicazione: (2024)
• Editorial: Genetics for non‐invasive risk stratification—Finding the needle in the haystack? Authors' reply
  di: Lana Bridi, et al.
  Pubblicazione: (2024)
• Editorial: Comparable Hepatic Fibrosis Risk Demands Equal Vigilance in Lean and Non‐Lean Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease—Authors' Reply
  di: Kaleb Tesfai, et al.
  Pubblicazione: (2025)
• Letter on ‘Inherited Genetic Risk of Liver Fibrosis in Lean Versus Nonlean Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD )’; Authors’ reply
  di: Kaleb Tesfai, et al.
  Pubblicazione: (2026)
• Repeatability of vibration‐controlled transient elastography versus magnetic resonance elastography in patients with cirrhosis: A prospective study
  di: Harris Siddiqi, et al.
  Pubblicazione: (2024)